480 related articles for article (PubMed ID: 18832655)
21. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
Yang Y; Zhang Q; Xu F; Chang C; Li X
Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
[TBL] [Abstract][Full Text] [Related]
23. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.
Tamaki H; Ogawa H; Ohyashiki K; Ohyashiki JH; Iwama H; Inoue K; Soma T; Oka Y; Tatekawa T; Oji Y; Tsuboi A; Kim EH; Kawakami M; Fuchigami K; Tomonaga M; Toyama K; Aozasa K; Kishimoto T; Sugiyama H
Leukemia; 1999 Mar; 13(3):393-9. PubMed ID: 10086730
[TBL] [Abstract][Full Text] [Related]
24. Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis.
Gonçalves AC; Alves R; Baldeiras I; Cortesão E; Carda JP; Branco CC; Oliveiros B; Loureiro L; Pereira A; Nascimento Costa JM; Sarmento-Ribeiro AB; Mota-Vieira L
Mol Carcinog; 2017 Jan; 56(1):130-148. PubMed ID: 26950655
[TBL] [Abstract][Full Text] [Related]
25. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome.
Knipp S; Strupp C; Gattermann N; Hildebrandt B; Schapira M; Giagounidis A; Aul C; Haas R; Germing U
Leuk Res; 2008 Jan; 32(1):33-7. PubMed ID: 17412418
[TBL] [Abstract][Full Text] [Related]
26. Abrupt evolution of Philadelphia chromosome-positive acute myeloid leukemia in myelodysplastic syndrome.
Fukunaga A; Sakoda H; Iwamoto Y; Inano S; Sueki Y; Yanagida S; Arima N
Eur J Haematol; 2013 Mar; 90(3):245-9. PubMed ID: 23240925
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
[TBL] [Abstract][Full Text] [Related]
28. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
Russell M; List A; Greenberg P; Woodward S; Glinsmann B; Parganas E; Ihle J; Taetle R
Blood; 1994 Aug; 84(4):1243-8. PubMed ID: 8049440
[TBL] [Abstract][Full Text] [Related]
29. Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes.
Yoshida A; Zokumasu K; Wano Y; Yamauchi T; Imamura S; Takagi K; Kishi S; Urasaki Y; Tohyama K; Ueda T
Haematologica; 2012 Sep; 97(9):1372-9. PubMed ID: 22419576
[TBL] [Abstract][Full Text] [Related]
30. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome.
Suciu S; Kuse R; Weh HJ; Hossfeld DK
Cancer Genet Cytogenet; 1990 Jan; 44(1):15-26. PubMed ID: 2293879
[TBL] [Abstract][Full Text] [Related]
31. GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome.
Zhou JD; Lin J; Zhang TJ; Ma JC; Yang L; Wen XM; Guo H; Yang J; Deng ZQ; Qian J
Cancer Med; 2017 Jan; 6(1):267-274. PubMed ID: 27891827
[TBL] [Abstract][Full Text] [Related]
32. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
Huh YO; Jilani I; Estey E; Giles F; Kantarjian H; Freireich E; Albitar M
Leukemia; 2002 Nov; 16(11):2249-52. PubMed ID: 12399969
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes.
Gyger M; Infante-Rivard C; D'Angelo G; Forest L; Lussier P
Am J Hematol; 1988 May; 28(1):13-20. PubMed ID: 3369432
[TBL] [Abstract][Full Text] [Related]
34. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
Estey EH; Keating MJ; Dixon DO; Trujillo JM; McCredie KB; Freireich EJ
Hematol Pathol; 1987; 1(4):203-8. PubMed ID: 3504436
[TBL] [Abstract][Full Text] [Related]
35. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups.
Gadji M; Adebayo Awe J; Rodrigues P; Kumar R; Houston DS; Klewes L; Dièye TN; Rego EM; Passetto RF; de Oliveira FM; Mai S
Clin Cancer Res; 2012 Jun; 18(12):3293-304. PubMed ID: 22539801
[TBL] [Abstract][Full Text] [Related]
36. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
37. Identification and validation of SRY-box containing gene family member
Zhou JD; Wang YX; Zhang TJ; Li XX; Gu Y; Zhang W; Ma JC; Lin J; Qian J
Clin Epigenetics; 2018; 10():92. PubMed ID: 30002740
[TBL] [Abstract][Full Text] [Related]
38. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
[TBL] [Abstract][Full Text] [Related]
39. AKAP12, a gene with tumour suppressor properties, is a target of promoter DNA methylation in childhood myeloid malignancies.
Flotho C; Paulun A; Batz C; Niemeyer CM
Br J Haematol; 2007 Sep; 138(5):644-50. PubMed ID: 17686059
[TBL] [Abstract][Full Text] [Related]
40. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
